CTRI/2014/01/004322已完成不适用
Effectiveness and Feasibility of Membrane Filtration for Safe Drinking Water in Rural India
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Diarrhoeal episodes in children during one year of follow up
研究概览
简要总结
Recruitment of study participants in the 3 sites of study began on October 1, 2013. We are yet to meet the total sample size of 80 children per site. Recruitment will be ongoing until we reach 80 children per site, the study team is tracking ANC’s for the purpose, and we hope to have completed recruitment by the end of the year or early next year.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 1.00 Month(s) 至 24.00 Month(s)（—）
- 性别
- All
入选标准
- •Children under 2 years of age (Follow up for enteric infections for babies will only begin after weaning).
排除标准
- •Children over 2 years of age.
结局指标
主要结局
Diarrhoeal episodes in children during one year of follow up
时间窗: Diarrhoeal episodes in children during one year of follow up
次要结局
- Percentage of water samples immediately post-treatment with no detectable coliforms in 100 ml of tested water(Water sampling is once monthly)
- Percentage of household stored water samples with no detectable coliforms in 100 ml of tested water(Water sampling of household samples will be accomplished in 10% of study households taken once in two months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgMedDRA version: 14.1 Level: PT Classification code 10000599 Term: Acromegaly System Organ Class: 10014698 - Endocrine disordersAcromegalyEUCTR2006-000297-72-GBBEAUFOUR IPSEN Pharma125
进行中（未招募）
不适用
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgAcromegalyMedDRA version: 8.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2006-000297-72-SEBEAUFOUR IPSEN Pharma68
进行中（未招募）
1 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgMedDRA version: 8.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2006-000297-72-GRBEAUFOUR IPSEN Pharma125
进行中（未招募）
不适用
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgAcromegalyEUCTR2006-000297-72-CZBEAUFOUR IPSEN Pharma68
已完成
3 期
Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant 40 to 120 mg per week (administered via subcutaneous route once or twice a week) in acromegalic patients failing to respond to lanreotide Autogel 120 mgGigantism10021112AcromegalyNL-OMON30806Ipsen Pharmaceuticals20